AstraZeneca (AZN) Receives a Hold From DZ BANK AG
Morgan Stanley Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Raises Target Price to $655
BMO Capital Maintains AstraZeneca(AZN.US) With Buy Rating, Raises Target Price to $89
Vertex Pharmaceuticals Analyst Ratings
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,125
Evercore Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Maintains Target Price $605
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Leerink Partners Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $136
AstraZeneca's Strong Q2 Performance and Positive Outlook Justify Buy Rating
Thermo Fisher Price Target Raised to $658.00/Share From $648.00 by TD Cowen
Redburn Atlantic Adjusts Price Target on Danaher to $280 From $260
Raymond James Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Raises Target Price to $660
Navigating 5 Analyst Ratings For Thermo Fisher Scientific
Jefferies Remains a Hold on AstraZeneca (AZN)
A Quick Look at Today's Ratings for Thermo Fisher Scientific(TMO.US), With a Forecast Between $600 to $664
Argus Research Initiates Danaher(DHR.US) With Buy Rating, Announces Target Price $300
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating
Cantor Fitzgerald Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $885
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), AstraZeneca (AZN) and Icon (ICLR)
Jefferies Adjusts Price Target on Thermo Fisher Scientific to $655 From $650, Maintains Buy Rating